Cargando…
The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review
OBJECTIVES: This systematic review aimed to assess the role of magnetic resonance imaging (MRI) in evaluating residual disease extent and the ability to detect pathologic complete response (pCR) after neoadjuvant chemotherapy for invasive breast cancer. METHODS: PubMed, the Cochrane Library, MEDLINE...
Autores principales: | Lobbes, M. B. I., Prevos, R., Smidt, M., Tjan-Heijnen, V. C. G., van Goethem, M., Schipper, R., Beets-Tan, R. G., Wildberger, J. E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609956/ https://www.ncbi.nlm.nih.gov/pubmed/23359240 http://dx.doi.org/10.1007/s13244-013-0219-y |
Ejemplares similares
-
Contrast-enhanced spectral mammography in recalls from the Dutch breast cancer screening program: validation of results in a large multireader, multicase study
por: Lalji, U. C., et al.
Publicado: (2016) -
Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006) -
MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
por: Goorts, Briete, et al.
Publicado: (2018) -
Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients
por: Goorts, Briete, et al.
Publicado: (2017) -
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer
por: Ring, A E, et al.
Publicado: (2004)